minge peamenüüsse
Eesti

Team

1
Modestas Jocius, PhD. Pharm Regional Manager Baltics

„On privileeg rakendada oma farmaatsia- ja ärindusalast haridust ning rohkem kui 25-aastast professionaalset kogemust, parandamaks harvikhaigustega inimeste elusid Eestis. Oleme siin tegutsenud alates 2009. aastast ning jätkame uuenduslike ja tõhusate ravilahenduste pakkumist!"

Faktid ja joonised

AOP Health on pühendunud farmaatsia- ja kliinilisele arendusele ning ravimite turustamisele juba üle 20 aasta.

Meie motivatsioon AOP Health'is on aidata harvikhaigusi põdevaid patsiente. Me saavutame selle koostöö Eesti tervishoiusüsteemi huvigruppidega. Farmaatsia- ja tervishoiutööstuse partnerlused on patsientide lahenduste leidmisel ja pakkumisel üliolulised, eriti harvikhaiguste ravis.

Eestil on eriline positsioon paljude riikide seas, kus AOP Health esindatud on. Sellel turul alustas ettevõte oma arendustegevust 2009. aastal koos kohaliku turunduse, müügi ning meditsiini valdkonna meeskonnaga kõigis kolmes terapeutilises rühmas.
 

100000
Inimesed
HARVIKHAIGUSTEGA PATSIENDID EESTIS
Euroopas on harvikhaigustena määratletud need haigused, mis esinevad vähem kui 5-l inimesel 10 000 elaniku kohta. Eestis on harvikhaigusi diagnoositud 100 000 inimesel.
SAADAOLEVAD RAVIMID
Eestis pakub AOP Health kaheksa ravimit.
8
Tooted
2
Valdkonnad
KAKS RAVIVALDKONDA
Eestis hõlmab AOP Health kahte ravivaldkonda: kardioloogia ja pulmonoloogia, neuroloogia ja ainevahetushäired.

History of more than 20 years means many significant milestones — in research,  social, business spheres and regulatory affairs — that were and are important for AOP Health.

1996

Foundation of AOP Health in Vienna

1999

The Orphan Regulation EC no 141/2000

2001

1st Approval of Anagrelide in Europe

2004

European Union Expansion

2005

Prostacyclin Analogues Approval

2005

JAK2 Discovery

2008

Renaissance of Interferon (IFNα)

2010

UDCA Designation

2010

Tetrabenazine Approval in Central Europe

2012

Nabilone Approval in Austria

2013

Start of the PROUD PV Study

2015

Beta-blocker for severe sepsis

2016

Pitolisant approval

2017

Landiolol approval

2018

Treprostinil and PAH

2019

BESREMi® Approval

Corporate culture

Thanks to many years of experience in the provision of complex and individualized treatments, AOP Health gained special expertise and market presence in the field of rare diseases.

Since its very start AOP Health has borne the social responsibility of further life quality improvement for patients with severe, rare and life-threatening diseases. We at AOP Health conduct intensive research for this purpose, believing that developing and providing solutions for patients is the most important part of the AOP Health corporate responsibility. When it comes to wanting the best for the patients, we stand side-by-side with each other as a team, with researches, physicians, therapists, caregivers, patient organizations and other stakeholders. 

AOP Health is keen to keep one of its greatest assets – it is closely networked with the key specialists in all markets and is therefore able to help patients with rare diseases from Austria throughout the world.

The future

Thanks to our advancements in the field of therapies, an increasing number of patients survive their disease or are able to live with it for a longer period of time. In the next few decades, personalized medicine, individual treatment opportunities will emerge more and more as the standard in AOP Health’s therapy concepts as well.

Novel technologies such as next-generation sequencing (NGS) will play an equally crucial role as the increasing quantities of big data and conclusions derived from the daily lives of patients also beyond the strictly regulated conditions of clinical trials, e.g. real-world evidence.

Furthermore, the increasing health competence, health literacy of patients and their family members will also determine the future of pharma and health care sector.